Company Overview of W. L. Gore & Associates, Inc.
W. L. Gore & Associates, Inc. manufactures electronics, fabrics, industrial, and medical products. It provides consumer products, including waterproof, windproof, and breathable garments, footwear and accessories, guitar strings, and vacuum cleaner bags; cables and cable assemblies; electronic and electrochemical materials, such as EMI shielding and grounding solutions, fuel cell components, and electrochemical device components; fabrics, including public safety, military, and fire and safety service fabrics; and fibers, such as sewing threads, weaving yarns, and rope fibers. The company also offers filtration products; medical products, including implantable medical devices and medical OEM ...
555 Papermill Road
Newark, DE 19711
Founded in 1958
Key Executives for W. L. Gore & Associates, Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2016.
W. L. Gore & Associates, Inc. Key Developments
W. L. Gore & Associates, Inc.'s GORE® TIGRIS® Vascular Stent Gains FDA Approval for Treatment of Peripheral Artery Disease
Aug 2 16
W. L. Gore & Associates, Inc. announced the U.S. Food and Drug Administration (FDA) approval of the GORE® TIGRIS® Vascular Stent, a dual-component stent with a unique fluoropolymer /nitinol design. The GORE TIGRIS device, which gained CE Mark approval in 2011, is a third generation, self-expanding stent. The device was designed explicitly to improve anatomical conformability with the natural movement of the knee when treating Peripheral Artery Disease (PAD). GORE® TIGRIS® Vascular Stent, a dual-component stent with a unique fluoropolymer /nitinol design the newly-approved GORE TIGRIS Vascular Stent uses a dual component structure, made from a single-wire nitinol stent with flexible and biocompatible fluoropolymer interconnections. The stent has been designed to weather biomechanical forces (extension, compression, flexion and torsion) without fractures, even in the most complex anatomies, namely in the superficial femoral artery (SFA) and proximal popliteal artery (PPA). In the U.S. clinical study that supported FDA approval of the GORE TIGRIS Vascular Stent, the TIGRIS stent was found to have zero fractures, while the control arm devices experienced a 27% fracture rate. The TIGRIS Vascular Stent has an innovative design that is very different from any of the other nitinol stents that currently use. The extreme flexibility of this stent makes it well suited for the superficial femoral artery and proximal popliteal artery, and the delivery system is highly accurate. The precision offered by this flexible, dual component device allows for easy insertion and predictable clinical outcomes, even in challenging anatomy. The new device builds on the company’s long history and experience with stenting, which spans more than two decades. The GORE TIGRIS Vascular Stent also features Gore's CBAS Heparin Surface, the proven, lasting heparin bonding technology designed to resist thrombus formation, a problem common in both bare metal and drug-eluting stents. End-point covalent bonding keeps heparin anchored to the stent surface, while the bioactive site remains free to interact with the blood to help prevent clotting. The evolution of peripheral stenting over the past decade has allowed for broader adoption of endovascular therapy for treating PAD. When physicians began placing stents in the SFA they were limited by first generation stent designs that had longitudinal metal connections which led to arterial stiffening, high fracture rates and poorer clinical outcomes. Improvements in second generation devices introduced helical interconnections to improve flexibility; however, their success in high flexion vessels, like the distal SFA and PPA, was still limited. The introduction of third generation stents, including the GORE TIGRIS Vascular Stent, allow for better adherence in some of the more intricate vessels in the body. PAD is prevalent in older populations, a rapidly growing demographic in developed countries. In the U.S. alone, approximately 8 to 12 million people suffer from some form of PAD. The disease can manifest in mild symptoms such as chronic leg pain, and more serious complications include poor wound healing, increased risk of stroke, and amputation. Endovascular treatment, via angioplasty and stenting of a blocked artery, is designed to treat PAD without the complications that can accompany open surgery.
W. L. Gore & Associates, Inc. Introduces New GORE Pressure Vent PE12 for High Airflow Levels
Jul 18 16
W. L. Gore & Associates, Inc. has introduced GORE Pressure Vent PE12, a new IPX8 pressure vent which reportedly delivers high airflow levels, for rapid pressure equalization in immersion-resistant mobile devices. When reaction time counts, count on PE12 for: faster pressure equalization; less acoustic distortion; and oleophobic ipx8 protection. New PE12 provides higher airflow efficiency at a smaller size, for more flexibility in small-part design for any mobile electronics. PE12 reacts faster to the rapid pressure changes that create transducer bias, so it can minimize acoustic distortion. With PE12, the user can count on immersion-resistant devices performing reliably in challenging environments. Only Gore's new PE12 pressure vent combines IPX8 protection with highest-ever airflow levels, to take venting response time and mobile electronics protection to a whole new level.
W. L. Gore & Associates Announces Clinical Study Results from the Gore Revise Clinical Study
Jun 28 16
W. L. Gore & Associates announced the publication of clinical study results from the Gore REVISE Clinical Study in the Journal of Vascular Surgery (J Vasc Surg) detailing the success of the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface (GORE VIABAHN Endoprosthesis) in AV access graft outflow interventions. Overall, the device performed significantly better compared to percutaneous transluminal angioplasty (PTA) alone for treatment of challenging AV access cases in a real-world patient population, both in terms of primary patency and in number of interventions over the study period. Notably, the Gore REVISE Clinical Study is the first AV access stent-graft study to include patients with thrombosed grafts and placement of the device across the elbow joint, further demonstrating the utility of the GORE VIABAHN Endoprosthesis in this demanding clinical application. Key findings from the Gore REVISE Clinical Study: The device delivered a 47% improvement in target lesion primary patency and a 48% improvement in circuit primary patency over PTA alone at six months; the device demonstrated a 50% increase over PTA in target lesion primary patency at six months when treating thrombosed AV access circuits; when placed across the elbow, the GORE VIABAHN Endoprosthesis delivered 72% target lesion primary patency at six months and 83% access secondary patency at 24 months (n=22); the Gore REVISE Clinical Study also showed median time to target lesion reintervention or graft abandonment with GORE VIABAHN Endoprosthesis was approximately twice that achieved with PTA (203 versus 108 days); and placement of GORE VIABAHN Endoprosthesis led to 27% fewer interventions both at the target lesion and in the dialysis access circuit over a 24-month period compared to PTA. According to the United States Renal Data System, there are over 700,000 patients with end-stage renal disease (ESRD) and nearly 90% of those patients are receiving hemodialysis. Arteriovenous grafts (AVG) are often used to create dialysis circuits for patients. Failing dialysis circuits often result in the placement of infection-prone central venous catheters (CVCs) while a new dialysis access circuit is surgically created and matured. Balloon angioplasty is a common fix in the event of a failing circuit, but many patients are unresponsive to the procedure, which has left a gap in treatment capabilities for difficult anatomies. The Gore REVISE Clinical Study demonstrated that placement of a stent-graft leads to better patient outcomes with reduced interventions, a positive finding for all stakeholders involved in the patient’s care.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|